No Data
Zhijiang Biotech: 2024 Annual Results Forecast
Zhijiang Biology (688317.SH): Expected loss of 0.11 billion yuan to 0.163 billion yuan in 2024.
Gelonghui reported on January 17 that Zhijiang Biology (688317.SH) announced a profit warning for the 2024 annual performance. According to preliminary calculations by the financial department, it is expected that the net income attributable to the owners of the parent company will incur a loss, with the net income ranging from -163 million yuan to -110 million yuan. The net income attributable to the owners of the parent company after deducting non-recurring gains and losses is estimated to be between -163 million yuan and -110 million yuan.
Gelonghui Announcement Highlights | LONGi Green Energy Technology: Projected loss of 8.2 billion yuan to 8.8 billion yuan for the fiscal year 2024; Haitian Shares: Controlling shareholder Haitian Investment plans to increase shareholding of 0.1 billion yu
【Hot Topics】Soho Holly Corporation (600128.SH): Currently, there is no marketing through Xiaohongshu as a trading platform. Zhejiang Tuna Environmental Science & Technology (603177.SH): The main operation does not involve new technologies, new industries, new business formats, or new models. Aimer Group (603511.SH): The company's Xiaohongshu channel revenue for the first three quarters of 2024 is 2.2308 million yuan. 【Project Investment】Daodaoquan Grain and Oil (002852.SZ): Plans to invest in a 1 million tons/year edible oil processing project in Weinan Economic Development Zone. Taotao Automotive (301345.SZ): Plans to invest in the construction of a production base in Thailand. 【Contract Bidding】Tianshan Electronics.
Zhijiang Biotech: Third Quarter Report 2024
Zhijiang Biology (688317.SH) plans to distribute 0.11 yuan per share and pay dividends on October 18th.
Zhi Jiang Biology (688317.SH) announced that the company's interim equity distribution for the first half of 2024 is proposed to be: cash dividend per share...
Zhijiang Biotechnology (688317.SH): The relevant biotechnology bills in the USA have not involved the company.
Zhejiang Biotechnology (688317.SH) stated on the interactive platform on September 18th that the relevant biotechnology legislation in the United States has not involved our company and has no direct impact. The company's main business is running normally and steadily. The company will closely monitor this matter.
Some Shanghai ZJ Bio-Tech Co., Ltd. (SHSE:688317) Shareholders Look For Exit As Shares Take 27% Pounding
